Treatment outcomes of advanced digestive well-differentiated grade 3 NETs
Authors
de Mestier, L.Lamarca, Angela
Hernando, J.
Zandee, W.
Alonso-Gordoa, T.
Perrier, M.
Walenkamp, A. M. E.
Chakrabarty, Bipasha
Landolfi, S.
Van Velthuysen, M. F.
Kats-Ugurlu, G.
Carminoa, A.
Ronot, M.
Manoharan, Prakash
Garcia-Alvarez, A.
Brabander, T.
García Gómez-Muriel, M. I.
Cadiot, G.
Couvelard, A.
Capdevilla, J.
Pavel, M. E
Cros, J.
Affiliation
L de Mestier, Gastroenterology and Pancreatology, Hopital Beaujon, Clichy, France.Issue Date
2021
Metadata
Show full item recordAbstract
There is no standardized treatment for grade 3 neuroendocrine tumors (G3 NETs). We aimed to describe the treatments received in patients with advanced G3 NETs and compare their efficacy. Patients with advanced digestive G3 NETs treated between 2010 and 2018 in seven expert centers were retrospectively studied. Pathological samples were centrally reviewed, and radiological data were locally reviewed. We analyzed RECIST-defined objective response (OR), tumor growth rate (TGR) and progression-free survival (PFS) obtained with first- (L1) or second-line (L2) treatments. We included 74 patients with advanced G3 NETs, mostly from duodenal or pancreatic origin (71.6%), with median Ki-67 of 30%. The 126 treatments (L1=74; L2=52) included alkylating-based (n=32), etoposide-platinum (n=22) or adenocarcinoma-like chemotherapy (n=20), somatostatin analogs (n=21), targeted therapies (n=22) and liver-directed therapies (n=7). Alkylating-based chemotherapy achieved the highest OR rate (37.9%) compared to other treatments (multivariable OR 4.22, 95% CI [1.5-12.2]; p=0.008). Adenocarcinoma-like and alkylating-based chemotherapies showed the highest reductions in 3-month TGR (p<0.001 and p=0.008, respectively). The longest median PFS were obtained with adenocarcinoma-like chemotherapy (16.5 months [9.0-24.0]) and targeted therapies (12.0 months [8.2-15.8]), while the shortest PFS were observed with somatostatin analogues (6.2 months [3.8-8.5]) and etoposide-platinum chemotherapy (7.2 months [5.2-9.1]). Etoposide-platinum CT achieved shorter PFS than adenocarcinoma-like (multivariable HR 3.69 [1.61-8.44], p=0.002) and alkylating-based chemotherapies (multivariable HR 1.95 [1.01-3.78], p=0.049). Overall, adenocarcinoma-like and alkylating-based chemotherapies may be the most effective treatments for patients with advanced G3 NETs regarding OR and PFS. Etoposide-platinum chemotherapy has poor efficacy in this setting.Citation
de Mestier L, Lamarca A, Hernando J, Zandee W, Alonso-Gordoa T, Perrier M, et al. Treatment outcomes of advanced digestive well-differentiated grade 3 NETs. Endocrine-Related Cancer. 2021 Jun.Journal
Endocrine Related CancerDOI
10.1530/erc-21-0109PubMed ID
34061764Additional Links
https://dx.doi.org/10.1530/erc-21-0109Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1530/erc-21-0109
Scopus Count
Collections
Related articles
- Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Any Benefit When Ki-67 Is ≥10%?
- Authors: Merola E, Alonso Gordoa T, Zhang P, Al-Toubah T, Pellè E, Kolasińska-Ćwikła A, Zandee W, Laskaratos F, de Mestier L, Lamarca A, Hernando J, Cwikla J, Strosberg J, de Herder W, Caplin M, Cives M, van Leeuwaarde R
- Issue date: 2021 Apr
- Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications.
- Authors: Fazio N, Milione M
- Issue date: 2016 Nov
- Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3).
- Authors: Ali AS, Grönberg M, Langer SW, Ladekarl M, Hjortland GO, Vestermark LW, Österlund P, Welin S, Grønbæk H, Knigge U, Sorbye H, Janson ET
- Issue date: 2018 Mar 6
- Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms.
- Authors: Heetfeld M, Chougnet CN, Olsen IH, Rinke A, Borbath I, Crespo G, Barriuso J, Pavel M, O'Toole D, Walter T, other Knowledge Network members
- Issue date: 2015 Aug
- Value of Tumor Growth Rate (TGR) as an Early Biomarker Predictor of Patients' Outcome in Neuroendocrine Tumors (NET)-The GREPONET Study.
- Authors: Lamarca A, Crona J, Ronot M, Opalinska M, Lopez Lopez C, Pezzutti D, Najran P, Carvhalo L, Franca Bezerra RO, Borg P, Vietti Violi N, Vidal Trueba H, de Mestier L, Schaefer N, Sundin A, Costa F, Pavel M, Dromain C, Knowledge Network
- Issue date: 2019 Nov